Pipeline
Positioning Ketamir-2 for an initial IND submission in the fourth quarter of 2024 and MIRA-55 in the first half of 2025.
| Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|
Ketamir-2Chemotherapy-induced peripheral neuropathy (CIPN) |
|
Phase 1 complete
|
|
|
Clinical
Preclinical